Posted On: 10/02/2014 11:50:37 AM
Post# of 30067
Re: biotechexpert #7527
We have a Phase 2b in Etoprazine for LID and ADHD, near commercial product with Lympro. The estimated revenue for those 2 products alone are 1.5B+ annually.
My point is Amarantus's pipleline is ahead of Alios and BP is willing to lay out 1.75B for them.
My point is Amarantus's pipleline is ahead of Alios and BP is willing to lay out 1.75B for them.
(0)
(0)
